Scientists have discovered that vitamin A, long considered a healthy nutrient, may actually be helping cancer tumors hide from your immune system.
Story Highlights
- Researchers at Princeton’s Ludwig Institute solved the decades-old “vitamin A paradox” – why lab studies showed it kills cancer cells but clinical trials linked high intake to increased cancer risk
- Cancer tumors exploit vitamin A byproducts to reprogram immune cells into tolerance mode, effectively disarming the body’s natural cancer-fighting abilities
- A new drug called KyA33 successfully blocked this immune suppression and slowed tumor growth in preclinical mouse studies
- The findings could revive stalled cancer vaccine programs and lead to entirely new immunotherapy approaches
The Vitamin A Cancer Paradox Finally Solved
For decades, cancer researchers faced a confounding mystery. Laboratory studies consistently showed that vitamin A derivatives could kill cancer cells or force them to mature into harmless forms. Yet large clinical trials revealed the opposite – people with high vitamin A intake faced increased cancer rates and higher mortality. This contradiction puzzled scientists for generations until researchers at Princeton University’s Ludwig Institute cracked the code.
The answer lies in cancer’s cunning ability to exploit vitamin A’s immune-regulating properties while simultaneously becoming resistant to its anti-cancer effects. Cancer cells overexpress an enzyme called ALDH1a3, which converts vitamin A into all-trans retinoic acid (RA). This RA then reprograms the very immune cells designed to attack tumors – dendritic cells – turning them into tolerance-promoting agents instead of cancer fighters.
Vitamin A may be helping cancer hide from the immune system https://t.co/eO4oxC6fGk
— inmunoes (@inmunoes) January 16, 2026
How Cancer Hijacks Your Immune System
Dendritic cells serve as the immune system’s intelligence officers, presenting foreign threats to T-cells and coordinating attacks against invaders like cancer. But when exposed to retinoic acid produced by tumors, these cellular guardians undergo a fundamental reprogramming. Instead of activating killer T-cells, they suppress immune responses and create an environment where cancer can thrive undetected.
Michael Esposito, one of the lead researchers, explained that cancers essentially have their cake and eat it too. They produce retinoic acid to suppress immunity while losing their own sensitivity to vitamin A’s growth-inhibiting signals. This dual manipulation explains why dietary vitamin A can fuel cancer growth despite its laboratory reputation as an anti-cancer agent.
Got a health question? Ask our AI doctor instantly, it’s free.
Breakthrough Drug Targets Previously Undruggable Pathway
The research team developed KyA33, a novel drug that blocks the enzymes responsible for converting vitamin A into immune-suppressing retinoic acid. In preclinical studies using mouse models of melanoma, KyA33 successfully restored proper immune function and slowed tumor growth. The drug works both as a standalone treatment and as an enhancer for cancer vaccines, potentially breathing new life into immunotherapy approaches that had stalled.
What makes this discovery particularly significant is that the retinoic acid pathway was previously considered “undruggable” among nuclear receptor pathways. The successful development of KyA33 represents a major pharmaceutical breakthrough that could extend beyond cancer treatment to diabetes and cardiovascular disease, where similar enzyme systems play roles.
Meet My Healthy Doc – instant answers, anytime, anywhere.
Clinical Implications and Future Directions
The researchers have founded a biotech company called Kayothera to advance KyA33 toward clinical trials. If successful in humans, this approach could transform cancer treatment by addressing one of immunotherapy’s fundamental challenges – the tumor microenvironment’s ability to suppress immune responses. The findings also suggest that cancer patients might benefit from monitoring or potentially limiting vitamin A intake during treatment.
This research doesn’t contradict vitamin A’s established benefits in other contexts, such as its FDA-approved use in treating acute promyelocytic leukemia through differentiation therapy. Rather, it highlights how cancer’s manipulation of normal biological processes can turn beneficial nutrients into unwitting accomplices. The key insight is that context matters tremendously in cancer biology – what helps in one situation may harm in another.
Watch:
Chat safely, anytime, with My Healthy Doc.
Sources:
Vitamin A may be helping cancer hide from the immune system
A nuclear target to revive anti-tumor immunity
Nuclear target to revive anti-tumor immunity
Derivative of vitamin A enhances tumor-killing effectiveness
